Clinical characteristics of breast cancer in patients with an NBS1 mutation.
To identify characteristic features of breast cancers associated with an NBS1 mutation. To estimate and to compare 10-year survival rates for patients with early-onset breast cancer, with and without an NBS1 mutation. 4,566 women with stage I to stage III breast cancer, diagnosed at or below age 50, were tested for a founder mutation in the NBS1 gene. Information on tumor characteristics and on treatments received was retrieved from medical records. Dates of death were obtained from the Poland vital statistics registry. Survival curves for the mutation-positive and negative sub-cohorts were generated and were compared and the effect of an NBS1 mutation on survival was determined using the Cox proportional hazards model. 4566 patients were enrolled in the study, of whom 53 (1.2 %) carried a NBS1 mutation. Mutation carriers were similar to non-carriers in terms of tumor receptor status, grade, and lymph node status. The 10-year survival for NBS1 mutation carriers was 81.2 % (95 % CI 70.1-94.1 %) and for non-carriers was 79.4 % (95 % CI 78.0-80.9 %). The presence of an NBS1 mutation is not associated with prognosis (HR = 1.21; 95 % 0.67-2.19). The survival of women with breast cancer and a NBS1 mutation is similar to that of patients without a NBS1 mutation.
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Połabska 4, 70-115, Szczecin, Poland.
T
T
Huzarski
C
C
Cybulski
A
A
Jakubowska
T
T
Byrski
J
J
Gronwald
P
P
Domagała
M
M
Szwiec
D
D
Godlewski
E
E
Kilar
E
E
Marczyk
M
M
Siołek
B
B
Gorski
R
R
Wiśniowski
H
H
Janiszewska
D
D
Surdyka
R
R
Sibilski
P
P
Sun
S A
SA
Narod
J
J
Lubiński
D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics*; D005260:Female; D018703:Founder Effect; D056726:Genetic Association Studies; D006801:Humans; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics*; D011379:Prognosis; D016016:Proportional Hazards Models; D012306:Risk; D055815:Young Adult
D018797:Cell Cycle Proteins; C112156:NBN protein, human; D009687:Nuclear Proteins